Eli Lilly and Co (NYSE:LLY) – Stock analysts at Jefferies Group lifted their FY2017 earnings per share (EPS) estimates for shares of Eli Lilly and in a research note issued to investors on Tuesday. Jefferies Group analyst J. Holford now expects that the company will post earnings per share of $4.25 for the year, up from their prior estimate of $4.14. Jefferies Group has a “Buy” rating and a $100.00 price objective on the stock. Jefferies Group also issued estimates for Eli Lilly and’s FY2018 earnings at $4.68 EPS and FY2020 earnings at $5.84 EPS.
Eli Lilly and (NYSE:LLY) last released its quarterly earnings results on Tuesday, October 24th. The company reported $1.05 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.03 by $0.02. Eli Lilly and had a return on equity of 30.27% and a net margin of 9.90%. The firm had revenue of $5.66 billion during the quarter, compared to analysts’ expectations of $5.52 billion. During the same period last year, the firm posted $0.88 EPS. The business’s revenue was up 9.0% on a year-over-year basis.
A number of other research analysts have also commented on the company. BMO Capital Markets reiterated a “sell” rating and issued a $71.00 price objective on shares of Eli Lilly and in a research report on Thursday, September 28th. Cowen reiterated a “buy” rating and issued a $95.00 price objective on shares of Eli Lilly and in a research report on Wednesday, October 4th. Goldman Sachs Group reiterated a “buy” rating and issued a $95.00 price objective (up from $92.00) on shares of Eli Lilly and in a research report on Thursday, October 5th. Morgan Stanley set a $86.00 price objective on Eli Lilly and and gave the company a “hold” rating in a research report on Friday, October 6th. Finally, Credit Suisse Group lowered Eli Lilly and from an “outperform” rating to a “neutral” rating and increased their price objective for the company from $84.23 to $88.00 in a research report on Tuesday, October 10th. Three research analysts have rated the stock with a sell rating, seven have issued a hold rating and nine have given a buy rating to the company. The company has an average rating of “Hold” and an average price target of $92.75.
Shares of Eli Lilly and (LLY) opened at $85.82 on Thursday. Eli Lilly and has a twelve month low of $74.00 and a twelve month high of $89.09. The firm has a market capitalization of $94,500.00, a price-to-earnings ratio of 40.87, a P/E/G ratio of 1.60 and a beta of 0.35. The company has a current ratio of 1.38, a quick ratio of 1.03 and a debt-to-equity ratio of 0.66.
The business also recently declared a quarterly dividend, which will be paid on Friday, March 9th. Stockholders of record on Thursday, February 15th will be given a $0.5625 dividend. This is a positive change from Eli Lilly and’s previous quarterly dividend of $0.52. This represents a $2.25 annualized dividend and a dividend yield of 2.62%. The ex-dividend date of this dividend is Wednesday, February 14th. Eli Lilly and’s dividend payout ratio (DPR) is currently 99.05%.
In other news, SVP Alfonso G. Zulueta sold 2,003 shares of the firm’s stock in a transaction on Friday, November 10th. The stock was sold at an average price of $83.67, for a total value of $167,591.01. Following the transaction, the senior vice president now directly owns 43,580 shares in the company, valued at approximately $3,646,338.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Lilly Endowment Inc sold 200,000 shares of the firm’s stock in a transaction on Wednesday, December 13th. The stock was sold at an average price of $88.20, for a total value of $17,640,000.00. Following the completion of the transaction, the insider now owns 123,084,104 shares in the company, valued at $10,856,017,972.80. The disclosure for this sale can be found here. Insiders sold a total of 251,088 shares of company stock worth $22,041,236 over the last 90 days. 0.20% of the stock is owned by corporate insiders.
Several large investors have recently bought and sold shares of LLY. Appleton Partners Inc. MA boosted its position in shares of Eli Lilly and by 4.9% in the 2nd quarter. Appleton Partners Inc. MA now owns 7,001 shares of the company’s stock worth $576,000 after purchasing an additional 325 shares during the last quarter. Bank of Montreal Can raised its stake in Eli Lilly and by 66.9% during the 2nd quarter. Bank of Montreal Can now owns 1,508,937 shares of the company’s stock worth $124,186,000 after buying an additional 604,577 shares during the period. First Financial Bank Trust Division raised its stake in Eli Lilly and by 11.3% during the 2nd quarter. First Financial Bank Trust Division now owns 5,705 shares of the company’s stock worth $469,000 after buying an additional 578 shares during the period. Gateway Investment Advisers LLC raised its stake in Eli Lilly and by 3.0% during the 2nd quarter. Gateway Investment Advisers LLC now owns 570,790 shares of the company’s stock worth $46,976,000 after buying an additional 16,549 shares during the period. Finally, Pennsylvania Trust Co raised its stake in Eli Lilly and by 78.7% during the 2nd quarter. Pennsylvania Trust Co now owns 14,020 shares of the company’s stock worth $1,154,000 after buying an additional 6,175 shares during the period. Institutional investors and hedge funds own 76.35% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Jefferies Group Equities Analysts Increase Earnings Estimates for Eli Lilly and Co (LLY)” was first reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this story on another site, it was illegally stolen and reposted in violation of United States & international copyright laws. The legal version of this story can be accessed at https://ledgergazette.com/2018/01/19/jefferies-group-equities-analysts-increase-earnings-estimates-for-eli-lilly-and-co-lly.html.
About Eli Lilly and
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.